David Gill joins Cannasouth
Cannasouth has appointed David Gill as Product Development Manager, who will take responsibility for bringing the company’s first medicinal cannabis products to the market.
Gill comes to Cannasouth after more than a decade with animal health multinational Argenta, where he was the chief scientific officer for the past seven years as head of the innovation division. Previously he was Argenta’s R&D manager, leading a team of 37 scientists.
Gill started his career in the Pharmacognosy Department of the University of London, where his lifelong passion began for medicinal products derived from natural sources. He then moved into mainstream pharmaceutical science, successfully developing products for both human and animal health.
Cannasouth chief executive officer Mark Lucas said the company is fortunate to have found someone of Gill’s calibre to join its leadership team.
“He has been with Argenta as it transitioned from a small company to a large multinational with a multimillion-dollar turnover. He played an important role in Argenta’s success and we look forward to tapping into his expertise as we work to develop next-generation cannabinoid medicines.”
In his new role, Gill will lead the research, development and formulation of cannabinoid products. He will have operational management of research projects as part of Cannasouth’s drive towards new product commercialisation. He will also be involved in leading research into delivery methods of cannabinoid medicines such as oral, sublingual, buccal, nasal, pulmonary, topical and transdermal.
Gill will relocate from Auckland to Hamilton to take up this role with Cannasouth, which he officially starts in October 2019.
This is supplied content and not commissioned or paid for by NBR.